CY1119149T1 - Αντικαρκινικη πρωτεϊνη συντηξης - Google Patents

Αντικαρκινικη πρωτεϊνη συντηξης

Info

Publication number
CY1119149T1
CY1119149T1 CY20171100632T CY171100632T CY1119149T1 CY 1119149 T1 CY1119149 T1 CY 1119149T1 CY 20171100632 T CY20171100632 T CY 20171100632T CY 171100632 T CY171100632 T CY 171100632T CY 1119149 T1 CY1119149 T1 CY 1119149T1
Authority
CY
Cyprus
Prior art keywords
fusion protein
domain
sequence
terminus
cancer fusion
Prior art date
Application number
CY20171100632T
Other languages
English (en)
Inventor
Jerzy Szczepan Pieczykolan
Sebastian Dominik Pawlak
Bartlomiej Maciej Zerek
Piotr Kamil Rózga
Original Assignee
Adamed Sp. Z O.O.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Sp. Z O.O. filed Critical Adamed Sp. Z O.O.
Publication of CY1119149T1 publication Critical patent/CY1119149T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Μια πρωτεΐνη σύντηξης που περιλαμβάνει την επικράτεια (α) η οποία είναι ένα λειτουργικό θραύσμα της αλληλουχίας πρωτεΐνης hTRAIL, το οποίο θραύσμα αρχίζει με ένα αμινοξύ σε μια θέση όχι χαμηλότερα από την hTRAIL95 ή ένα ομόλογο του εν λόγω λειτουργικού θραύσματος που έχει τουλάχιστον 70% ταυτότητα αλληλουχίας· και την επικράτεια (β) η οποία είναι μια αλληλουχία αντιαγγειογενετικού πεπτιδίου τελεστή, όπου η αλληλουχία της επικράτειας (β) συνδέεται στο C-τελικό ή στο Ν-τελικό άκρο της επικράτειας (α). Η πρωτεΐνη σύντηξης μπορεί να χρησιμοποιηθεί για τη θεραπεία καρκινικών ασθενειών.
CY20171100632T 2011-01-05 2017-06-15 Αντικαρκινικη πρωτεϊνη συντηξης CY1119149T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL393578A PL219845B1 (pl) 2011-01-05 2011-01-05 Przeciwnowotworowe białko fuzyjne
PCT/EP2012/050145 WO2012093158A1 (en) 2011-01-05 2012-01-05 Anticancer fusion protein

Publications (1)

Publication Number Publication Date
CY1119149T1 true CY1119149T1 (el) 2018-02-14

Family

ID=45476512

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100632T CY1119149T1 (el) 2011-01-05 2017-06-15 Αντικαρκινικη πρωτεϊνη συντηξης

Country Status (25)

Country Link
US (1) US9175059B2 (el)
EP (1) EP2661496B1 (el)
JP (1) JP5797773B2 (el)
KR (1) KR101950043B1 (el)
CN (1) CN103228788B (el)
AU (1) AU2012204900B2 (el)
BR (1) BR112013016980B1 (el)
CA (1) CA2814597C (el)
CY (1) CY1119149T1 (el)
DK (1) DK2661496T3 (el)
EA (1) EA025830B1 (el)
ES (1) ES2628377T3 (el)
HR (1) HRP20170905T1 (el)
HU (1) HUE032576T2 (el)
IL (1) IL226205B (el)
LT (1) LT2661496T (el)
ME (1) ME02756B (el)
MX (1) MX339203B (el)
PL (2) PL219845B1 (el)
PT (1) PT2661496T (el)
RS (1) RS56095B1 (el)
SG (1) SG190049A1 (el)
SI (1) SI2661496T1 (el)
UA (1) UA108778C2 (el)
WO (1) WO2012093158A1 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970478B1 (en) 2013-03-12 2020-05-06 Molecular Templates, Inc. Cd20-binding immunotoxins for inducing cellular internalization and methods using same
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
US10875903B2 (en) 2013-05-06 2020-12-29 China Pharmaceutical University Bifunctional fusion proteins to inhibit angiogenesis in tumor microenvironment and to activate adaptive immune responses and the genes and uses thereof
WO2015191764A1 (en) 2014-06-11 2015-12-17 Molecular Templates, Inc. Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same
WO2015113005A1 (en) 2014-01-27 2015-07-30 Molecular Templates, Inc. Mhc class i epitope delivering polypeptides
EP3102245B1 (en) 2014-02-05 2021-09-08 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
CN108064247B (zh) 2015-02-05 2022-06-03 分子模板公司 包含志贺毒素a亚基效应物区域的多价cd20结合分子及其富集组合物
US10428132B2 (en) 2015-02-11 2019-10-01 West China Hospital, Sichuan University Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
US20210008208A1 (en) 2016-12-07 2021-01-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
US20200024312A1 (en) 2017-01-25 2020-01-23 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
CA3097178A1 (en) 2018-04-17 2019-10-24 Molecular Templates, Inc. Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69328091T2 (de) 1992-04-29 2000-10-12 Georgetown University, Washington Bindungspeptide zur interaktion mit wachstumsfaktoren als liganden des rezeptors des epidermiswachstumsfactor und des erbb-2-rezeptor
IL149261A0 (en) 1995-06-29 2002-11-10 Immunex Corp Antibodies that bind a tnf related apoptosis inducing ligand (trail) peptide
JPH11513249A (ja) * 1995-09-27 1999-11-16 メディカル・リサーチ・カウンシル プロテアーゼにより開裂可能なタンパク質を組込んだ組換えウイルス
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
DE10247755B4 (de) * 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
CN1257187C (zh) 2003-10-22 2006-05-24 上海恰尔生物技术有限公司 钙网蛋白－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
US7431915B2 (en) * 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
ATE501256T1 (de) 2003-11-03 2011-03-15 Beijing Sunbio Biotech Co Ltd Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung
CN1256347C (zh) * 2003-12-10 2006-05-17 中国人民解放军第二军医大学 激肽原第五结构域－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
WO2007022157A2 (en) 2005-08-16 2007-02-22 Genentech, Inc. Apoptosis sensitivity to ap02l/trail by testing for 'galnac-t14 expression in cells/tissues
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
CL2009001191A1 (es) 2008-05-14 2010-07-02 Genentech Inc Uso del peptido apo2l/trail porque sirve para preparar un medicamento para tratar el cancer de pulmon y el linfoma de hodkin.
CN102137869B (zh) 2008-06-30 2018-07-06 宾夕法尼亚大学 Fn14/TRAIL融合蛋白
PL391627A1 (pl) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
CA2814595C (en) * 2010-12-03 2020-06-16 Adamed Sp. Z O.O. Anticancer fusion protein

Also Published As

Publication number Publication date
ME02756B (me) 2018-01-20
JP2014504868A (ja) 2014-02-27
SG190049A1 (en) 2013-06-28
RS56095B1 (sr) 2017-10-31
MX339203B (es) 2016-05-13
AU2012204900B2 (en) 2014-12-18
CA2814597A1 (en) 2012-07-12
PL219845B1 (pl) 2015-07-31
EA201391005A1 (ru) 2013-11-29
BR112013016980A2 (pt) 2020-08-04
HRP20170905T1 (hr) 2017-09-08
KR20140036143A (ko) 2014-03-25
CN103228788B (zh) 2016-09-07
PL2661496T3 (pl) 2017-08-31
BR112013016980B1 (pt) 2022-10-11
DK2661496T3 (en) 2017-07-03
US9175059B2 (en) 2015-11-03
PL393578A1 (pl) 2012-07-16
WO2012093158A1 (en) 2012-07-12
JP5797773B2 (ja) 2015-10-21
UA108778C2 (xx) 2015-06-10
EP2661496A1 (en) 2013-11-13
US20130288963A1 (en) 2013-10-31
HUE032576T2 (en) 2017-09-28
EA025830B1 (ru) 2017-02-28
LT2661496T (lt) 2017-07-10
ES2628377T3 (es) 2017-08-02
SI2661496T1 (sl) 2017-09-29
KR101950043B1 (ko) 2019-02-19
MX2013007872A (es) 2013-07-30
PT2661496T (pt) 2017-06-26
EP2661496B1 (en) 2017-03-15
IL226205A0 (en) 2013-07-31
IL226205B (en) 2018-10-31
CN103228788A (zh) 2013-07-31
CA2814597C (en) 2019-01-08
NZ609219A (en) 2014-06-27
AU2012204900A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
CY1119149T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
CY1116646T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
CY1120055T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
CY1122079T1 (el) Πρωτεϊνες επαναληψης διπεπτιδιου ως θεραπευτικος στοχος στις νευροεκφυλιστικες νοσους με επεκταση επαναληψης των εξανουκλεοτιδιων
CY1121900T1 (el) Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
CY1122691T1 (el) Πρωτεϊνες δεσμευσης αλβουμινης ορου
CY1116099T1 (el) Πρωτεϊνη συντηξης κατα του καρκινου
CY1121953T1 (el) Κυτταροδιεισδυτικα πεπτιδια και μεθοδοι παρασκευης και χρησης αυτων
CY1122564T1 (el) Μορια δεσμευσης μονhς αλυσιδας που περιλαμβανουν ν-τελικο αβρ
EA201491049A1 (ru) Противораковый слитый белок
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
CY1124435T1 (el) Νουκλεικα οξεα που κωδικοποιουν ανθρωπινα αντισωματα σε sialyl-lewis α
CY1119751T1 (el) Υλικα και μεθοδοι για θεραπεια ή προληψη ασθενειων που σχετιζονται me her-3
CY1120772T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
CY1126072T1 (el) Περιοχες gla ως θεραπευτικοι παραγοντες
ES2676023T3 (es) Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
CY1118200T1 (el) Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσης
AR095432A1 (es) Proteínas de unión a antígeno
ES2676499T3 (es) Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
CY1119737T1 (el) Νεες συνθεσεις και μεθοδοι
CY1120132T1 (el) Χρηση ρ3 πρωτεϊνων συντηξης βακτηριοφαγου ως παραγοντων δεσμευσης αμυλοειδους
CY1121347T1 (el) Πρωτεϊνη συντηξης
CY1121427T1 (el) Χρηση ενος μοριου mir172 για τη μειωση της φλεγμονhς